My interest in this problem was aroused during a study of drug-induced mood changes in volunteer subjects (Lasagna & von Felsinger 1954) . Like other investigators, we were often in a position where experiments could be done with ease only on paid volunteers. From time to time we, our technical help, or casual observers had been struck by the behaviour of some of these volunteers, who seemed to fall outside the range of 'normal' as judged by our standards, neither excessively loose nor puritanical. Routine Rorschach tests and psychological interview material in 56 young men from 21 to 28 years of age revealed what seemed to be an unusually high incidence of severe psychologic maladjustment.
Data from several college guidance clinics tended to confirm the suspicion that our volunteer group was indeed an abnormal sample in regard to personality problems and that it was showing an incidence of serious psychological difficulties that was at least twice as high as one would have expected in an unselected college population. Some volunteers were primarily interested in monetary rewards whereas others were hoping to find professional advice and help or a drug that might prove 'the golden key' to their personality problems. Others volunteered in a search for new experience, much as a potential drug addict might experiment with a variety of agents. Finally, there were subjects who desired temporary relief from the boredom of everyday life, or who sought sexual satisfaction in an essentially guilt-free environment, or who sought to gratify self-destructive urges. There was a contamination of 'primary' drug effects by the psychological interpretation of, or reaction to, such effects on the part of our volunteers. The basic personality of the subject and the reasons for volunteering seemed to modify the total response to a varying extent, not infrequently to an extreme degree.
Our studies of the reactions to lysergic acid derivatives (von Felsinger et al. 1956 ) and commonly used central nervous system stimulants and depressants (von Felsinger et al. 1955 ) yielded similar results.
The administration of amphetamine or opiates to volunteer subjects produces considerable variability in response. Most healthy volunteers are made euphoric and mentally stimulated by amphetamine but a minority react in an opposite direction with depression and sedation. There is a fairly sharp contrast in the psychologic profiles of those of our subjects who were unequivocally stimulated by amphetamine and those who were unequivocally sedated. The differential responses to morphine and heroin followed an analogous pattern. Most normal subjects find morphine and heroin unpleasant but the small minority of subjects who found morphine and heroin unequivocally pleasant were characterized by an interesting constellation of personality traits and by Rorschach responses which fit in with at least one theoretical construct in regard to personality structure predisposing to narcotic addiction.
Several studies attempting to identify individuals likely to respond predictably in a positive or negative way to placebos have also indicated a relationship between personality dynamics, previous learning and attitudes, and the response to the injection of an inert substance ). We have not been able to identify sex as an important determinant of placebo reactivity but age, years of formal education, and attitudes towards drugs, doctors, nurses, hospitals and church membership seem to be important.
Other studies, such as those of Blumberg et al. (1954) , make a good case for the hypothesis that psychological differences between patients with malignant disease, as measured by relatively simple tests such as the Minnesota Multiphasic Personality Inventory, are importantly related to differences in the patient's prognosis and thus presumably to the response to therapy.
Again, hypertension in Negroes in the U.S. carries a prognosis considerably more lugubrious than the same disease in whites. The rapid development of complications and the occurrence of early death are phenomena often seen in these Negro patients, and response to medications appears considerably less satisfactory than in whites. Certain factors, although speculative, such as the emotional stresses suffered in our civilization by Negroes and the problem of population density, may be operative under these conditions. I am particularly interested in the latter factor -because of the work of our laboratory in pursuing the lead of Gunn & Gurd (1940) and the fascinating experiments of Chance (1946, 1947) on the remarkably enhanced toxicity of central nervous system stimulants in animals in a crowded environment. The presence of other mice in close proximity renders a lethal outcome to amphetamine much more likely, and certain drugs (central depressants) can protect against this aggregation effect (Lasagna & McCann 1957) . Increasing population density of rodents affects the size and presumably the activity of their adrenal glands (Thiessen & Rodgers 1961) , organs which are acknowledged to be related in some important way to arterial blood pressure, and perhaps to the vascular complications of hypertension.
What might be termed the sociopsychology of therapeutics is evident in many other situations, such as the 'observer error' in 'objective' measurements of response to medication such as X-ray films and sphygmomanometer readings (Witts 1959) . But there are probably other, more subtle, observer errors.
For example, in an evaluation of several hypnotic drugs in a group of hospitalized psychiatric patients (Imboden & Lasagna 1956 ) we had the opportunity to contrast objective reports by nurses with the subjective evaluations of the patients. In general, agreement was good, but there were a number of rather dramatic discrepancies. Such discrepancies were especially frequent in depressive patients, who were more likely to understate the amount of sleep they had obtained during the night. Since that time I have become aware of information, both old and new, testifying to the distorted time sense of depressed patients (Mezey & Cohen 1961); for depressed patients time seems to pass more slowly than for non-depressed patients.
In a study (Hohn et al. 1961 ) on depressed patients in which imipramine and a placebo were compared we saw another kind of discrepancy. Here we found a significant tendency for ward attendants to see more improvement in patients than was observed by a trained psychiatrist making an independent evaluation of the behaviour of these experimental subjects.
Similarly, in obstetrical wards it was found that about half the evaluations of the severity of pain in labour and the adequacy of pain relief obtained from patients and the doctors in charge of them coincided exactly. In 80% of the cases where there was a discrepancy between doctor and patient the doctor tended to believe the woman had less pain than the woman herself believed. There are probably many other situations in therapeutics where patients are much less impressed by the effects of therapy than are the doctors responsible for their care.
Again, the psychiatrist who is the medical student's physician will often present a more favourable view of the 'progress' of the student than will his colleagues. The psychiatrist may be unconsciously biased towards seeing improvement in his desire to achieve therapeutic benefit. Alternatively, or when there is some improvement, the psychiatrist may be becoming more tolerant to the patient's aberrant behaviour, or the patient anxious to please the physician may be consciously or unconsciously putting his best foot forward in the interview situation. I have always thought this last possibility was primarily responsible for the interesting phenomenon observed in several studies our group performed in patients hospitalized for chronic diseases . We were measuring the response to a single inert yellow tablet given each day with the suggestion that it might influence appetite and feelings of energy in a desirable direction. After a steady base-line period there was little or no change for the first day or two of placebo medication, but then an increasing positive effect over time. Some patients would volunteer the information, on the first and second day, while they were reporting little or no change: 'You know, it takes these pills a while to take hold, Doctor.' It must be difficult for a social being to disappoint a physician day after day with responses of 'No improvement, Doctor'.
The impact of the interviewer is well known to poll takers and to sociologists, since there is good evidence that the nature of the questioner may affect the response elicited in a dramatic manner. In many situations it is highly desirable to have multiple points of view in regard to therapeutic effect, since there is a no single magic source of information which can be relied upon to give the 'true picture' in all cases.
Several years ago we were allowed to participate in the planning of a study on the effects of psychopharmacologic agents in a group of disturbed children (Cytryn et al. 1960) . In this study there was an opportunity to obtain useful information from several sources: the children, their parents and their teachers. In this particular instance there was reasonably goodthough far from completeagreement between these sources of information, but such is not always the case. Even in this experiment, the coefficients of correlation between improvement scores obtained from two sources of information ranged from 0-68 to as low as 0-52. This leads us to the broader question of the evaluation of drug effects in the natural setting. The practice of medicine is unfortunately often limited in its observations to short and relatively unimportant bits of the patient's existence, in the office, the clinic or the hospital ward. Home conditions can render hospital treatment almost meaningless. The administration of antihypertensive drugs has become more rational since the introduction of blood pressure taking at home has supplemented blood pressure readings in the clinic or hospital. The 1960 Veterans Administration Study has shown that certain effects of treatment, which were obvious in the home readings, were not at all apparent in office readings. In the area of mental diseases particularly, it is surely more important to know how an individual functions at home and on the job rather than how he is adjusting to his doctor.
One extremely important aspect of therapeutics which has received extraordinarily little attention is the matter of the filling and taking of prescribed remedies. A few spot surveys have indicated that a rather large percentage of prescriptions may never be filled, or at least may never be ingested. In a study on sulphonamides we were shocked to learn that a fair percentage of patients were paying little or no attention to directions and either taking all the pills within a short time or takinglittle of the medication at anytime. The hazards of outpatient trials are considerable and the psychological problems involved in the ingestion of drugs and the following of directions in general must be realistically faced in our evaluation of therapeutic results.
The Development ofPhysicians' Attitudes to Drugs
In a study on the spread in usage of a new antibiotic drug in four midwestern communities over a period of almost a year and a half, Coleman et al. (1959) found that for most doctors it meant an addition to whatever drugs of this type they were already using rather than a substitution. Only slowly, if at all, did some of the doctors stop using other drugs. The incidence of the first use of the new antibiotic was related to the number of journals received by the physician, and the number of specialty meetings attended. A doctor's ten-dency to innovate is not only a function of something about him as an individual, but alsoand perhaps more strongly -a function of his social location among other doctors. In an age where we hear a great deal about the importance of journals, meetings, detail men, and drug-house advertisements, we have perhaps paid too little attention to the personality of the doctor and to the social and professional contacts a doctor has with his colleaguestwo factors which serve important psychological functions in the diffusion and acceptance of a new therapeutic practice.
It is important that we consider also the psychological reasons for the perpetuation of outmoded beliefs. We have for a long time been impressed by the myth of heroin. Most doctors in my country believe that heroin is a far more dangerous drug than morphine in its ability to produce drug addiction. Our own investigations (Lasagna et al. 1955) , and some performed at the Addiction Research Center in Lexington, Kentucky, would indicate precious little difference in the spectrum of activity of heroin and morphine. One suspects that the popularity of heroin as an illegal drug of addiction in the U.S. is primarily related to the ease of smuggling a drug which is, milligram for milligram, more potent than morphine. Similarly, the results of a poll of physicians on the merits and demerits of the three most commonly prescribed barbiturates, pentobarbital, secobarbital and phenobarbital, gave by and large a picture in regard to speed of onset, duration of effect and tendency to produce sideeffects which mimics that described in the past by some of the most influential American textbooks.
In point of fact, for equivalent single doses our own data (Lasagna 1959 ) and those of others (Goldstein 1953 , Belleville & Fraser 1957 would suggest that pentobarbital and secobarbital are essentially similar in effect, and not, on the average, significantly different either in onset or duration of effect or in side-effects. This discrepancy between fact and held opinion is partly related to the difficulty of obtaining accurate information without suitable controlled trials in this field, in part to the absence of feedback' for physicians in regard to these drugs (Lasagna 1959) and in large part to the perpetuation of myths by our textbooks and medical teaching. In conclusion, it seems to me unfortunate that therapeutics has paid only lip service for so long to the importance of psychological and sociological variables. Too often we have had a sterile dichotomy between those individuals who tend to forget variability of response and the importance of non-drug variables, and those individuals so 'Doctors are, for example, almost never around to observe the effects of hypnotic drugs. 12 obsessed with the complexity of variables involved in drug responses that they are intellectually paralysed and never attempt the dissection of these variables. Medicine is now in a position to till the fertile fields between these barren poles. (1955) 
Differences between Physicians as Revealed by Clinical Trials
Milieu, past experience of the individual (at least in so far as the reaction to placebos is concerned) and the personality of the physician are well known to determine the choice as well as the outcome of many treatments. Feldman (1956), who found that the extent to which treatment with drugs of-321 patients by 37 therapists at the Menninger Clinic was successful varied with the enthusiasm of the latter for drug therapy, argued that there was a need to record the characteristics of the research worker as carefully as the other elements of the research design. To Sherman's statement of the problem of the choice of drug confronting the physician: 'Will this drug benefit this particular patient with his unique background, motivation for treatment, personality structure and symptoms' (Sherman 1959) one may add 'in the hands of this particular doctor'! Klerman is one of the few workers to have begun work on the necessary study of personality differences between physicians . (Klerman et al. 1960) : he and his colleagues discovered that, amongst psychiatrists, the tendency to treat with drugs is positively correlated with the degree of 'authoritarianism'.
Such influences can take many forms: from the qualities of the physician-patient relationship, through the variation due to observer error, to the ultimate failure to draw legitimate inferences from observations made. The results of the influences can be as concrete as a significant increase, or decrease, in free gastric acid following injection of a placebo (Wolf 1959); or in blood pressure changes following veratrum alkaloids (Shapiro et al. 1954 ). More usually, they determine whether a patient is considered to be improved or unchanged or even made worse by treatment. The preference of patients for one treatment over another, judged by symptom check lists or their own evaluation of changes in a double-blind comparison, might be expected to be subject to such random influences that systematic tendencies would not be observable. However, Canter and his colleagues have shown that this is by no means always the case (Uhlenhuth et al. 1959) . In a double-blind study on the usefulness of phenobarbitone, meprobamate and placebo in relieving the anxiety of neurotic outpatients, they used two clinicians chosen for their differing personalities by devices previously found by Betz & Whitehorn (1956) to discriminate between psychotherapists with different success rates in treating schizophrenia. One of the two (the more enthusiastic in manner) was able to demonstrate on his patients that both drugs were significantly different from the placebo, but not from each other: the other found no differences at all.
Perhaps such results might be expected when the participating therapists were deliberately chosen to be as unlike each other as possible, and in a specialty particularly sensitive to the human element in therapy. But the possible consequences for the outcome of clinical trials in other fields are obvious, especially when these depend upon simply expressed patient preferences for the different treatments. Dr R M Mason (London Hospital Department of Physical Medicine) and I, therefore, examined patient preferences elicited by physicians during a trial of placebo, phenylbutazone and C20410 Ciba in the symptomatic treatment of female out-patients with active inflammatory joint disease. The procedure, which was double blind and used patients as their own controls, has been fully described in a report which draws attention to the necessity of estimating patient co-operation, or willingnes s to follow instructions, and of using the information so obtained to compare the usefulness of the remedies more reliably (Joyce & Mason 1961, Joyce 1962). It was not possible for administrative reasons to arrange that patients were seen in a balanced order by each participating physician at one of the four monthly visits, but it turned out that each patient saw an average of 2-4 physicians, and the three physicians carrying most of the load saw about a quarter each of the patients, with the remaining quarter shared about equally among three others (Table 1) . At each visit the patient compared the present and previous treatment, and this, in addition to giving information about preferences, led to an overall measure of 'enthusiasm' for the trial. If, for example, a patient gave a more favourable judgment to the second treatment on each occasion that she was seen she scored the maximum: +3. A more favourable view of the earlier treatment each time gave a minimum 'enthusiasm' score: -3. On the final visit, she stated her overall preference for the first, second or third treatment, or no preference at all.
It can be seen that the information obtained by the physicians differed widely. Physician B obtained an overwhelming judgmentinfavour of phenylbutazone, and only one patient expressed no preference. The results obtained by the others differed from this and from each other, as they did from the enthusiasm score elicited by B. The patterns are significantly different, and it is not easy to see how differences of such magnitude could have occurred in a double-blind trial (even though balanced exposure to different physicians was not part of the experimental design) unless one or other of the participants was succeeding in extracting statements from the patients that more faithfully reflected the 'true' state of affairs. If statistical artifacts be excluded as an explanation (and there is no moreand no lessreason to consider them here than on any other occasion when any level of probability for chance differences is specified), the 'successful' physician must have been B: if there were really as little difference between the treatments as the average of all the others' observations would suggest, such an overwhelming verdict for one of the four possible outcomes would be very unlikely to have occurred by chance. The lower enthusiasm score elicited by B suggests that this observer may have allowed patients more time to make up their minds; or have been less inclined to ask leading questions; or simply that he (or shethe identity of the participants has not been revealed even to them because further investigations are intended) contrived not to generate an undiscriminatingly positive (and possibly insincere) attitude to the whole situation.
Some confirmation is provided by observations on the mean number of active joints and toxic signs observed by the physicians, and ofsymptoms reported on questionnaires completed by the patients at the same attendances, but in the absence of the physicians (Table 2 ). On the two objective measures the score of thepatients seen by B is the lowest, whereas the subjective scores show no significant differences. It seems possible that B was more realistic, if not harder hearted. Had the evaluation of the remedies depended simply upon patient preferences expressed to all physicians, one would have had no reason to believe that C20410 was more active than a placebo: had B not participated, not even phenylbutazone would have been regarded as successful. When the extent to which patients cooperated in taking their medication was estimated and taken into account, both C20410 and phenylbutazone were in fact clearly seen to be useful (Joyce 1962).
However, some trials rely on preferences alone, and the risk of error that they run for the reasons discussed above may be considerable. This is not to say that there are few circumstances in which the patient's own preference is the correct indicator of therapeutic successthere are probably many such occasions, provided that the preference is reliably expressed. It is possible that some physicians are better than others at obtaining reliable judgments, and it is worth while to enquire why. It may also be that the design of clinical trials employing more than one observer should be arranged to take this kind of observer variation into account. In the present paper we shall describe a pilot study designed to assess and compare the contribution to treatment outcome of three variables:
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(1) The patient's attitude to physicians and treatment, (2) his degree of neuroticism, and (3) his degree of extraversion.
Attitude
When attempting to study a relationship as complex as that between doctor and patient, it is advantageous to employ a theoretical model, simplified in detail but which, none the less, enables testable predictions to be made. Gliedman et a!. (1957) have argued that conditioning of the Pavlovian type provides such a model. In the course of their work on animals they observed that a conditioned response could be modified or inhibited by the presence of the experimenter or other individuals with whom the animals had been in contact. For instance, they described how persons associated with an animal during the genesis of an experimental neurosis could subsequently, by their presence alone, precipitate disturbances of behaviour in the animal. In other words, the experimenter himself can come to function as a complex conditioned stimulus. Such experiments, they say, 'seem to indicate that the meaning of a person to the animal can have pronounced effects on the reactions which appear'. They go on to suggest that 'the impact of the doctor on the patient can be such as to modify or worsen the disease, depending to some degree on the meaning the patient has learned about certain or all help-giving situations in the past. To the extent that doctors and therapy have come to stand for relief of distress, the patient's response is likely to be favourable'. On the basis of this hypothesis it was predicted that patients who had acquired favourable attitudes to doctors and medical treatment would respond better to treatment than those less favourably disposed.
To measure these attitudes a scale was constructed, as follows: Thirty-five statements expressing either favourable or unfavourable opinions about doctors and treatment were given to 75 students who were asked to record whether they 'strongly agreed', 'agreed', 'disagreed', 'strongly disagreed' with, or were 'uncertain' about the opinion expressed in each statement. These responses were scored on a 5-point scale; favourable responses always getting a score of 4 or 5. To test whether the subjects' answers to these items were consistent, scores on the 35 items were intercorrelated and the resulting matrix factor analysed by the principal components method.' The analysis showed that all items but one had a positive loading on the first factor and that this factor accounted for by far the largest proportion of the total variance (19 %). We concluded that the scale reflects a general attitude which to some degree affects the subject's responses to questions relating to numerous and varied aspects of medical practice and treatment. We then took the 20 items with the highest loadings on this first factor (04 or above) as being the best measure of an individual's general attitude towards doctor and treatment. This scale had a split-half reliability of 085. In a further study we found that it had a test-retest reliability of 063 over a period of a month. These results indicate that our scale has a high degree of internal consistency and that the attitude measured is reasonably stable over time. ' This analysis was carried out for us by Dr Benedict Nixon at the University of London Computer Centre.
Personality
A number of studies on both patients and normal volunteer subjects have followed the early work of which demonstrated personality differences between placebo reactors and non-reactors. The patient's degree of neuroticism and extraversion appeared to be important personality factors affecting the degree of therapeutic responses. Therefore, these two variables were included in the present study and were measured by means of the Maudsley Personality Inventory (M.P.I.) (Eysenck 1959) .
Patients and Treatment
The personality and attitude scales were administered to 22 university students prior to their participation in a double-blind clinical trial of a new drug, pemoline, claimed to be valuable for the treatment of fatigue. The scales were introduced as part of an independent Medical Research Council study, and were completed in private. In this way we hoped to obtain maximum frankness on the part of the patients.
Clinically, the patients all suffered from persistent and disabling fatigue without clear physical cause. Most had, in addition, other symptoms such as headache and insomnia, but patients whose predominant symptoms were of overt anxiety or tension were not included. Coming from a university population the patients were relatively homogeneous in respect of age. With regard to personality, all but one of the 22 patients completing the trial scored above Eysenck's (1959) . I scale both the mean and standard deviation approximated to those reported by Eysenck. Each student received the active preparation for one week and a placebo of identical appearance for a second week, the order of treatments being balanced. The method of assessing the effects of treatment was that used by Raymond et al. (1957) . The patients were asked at the end of every day to note the effects of the tablets by stating whether they had experienced either a 'very good effect', 'good effect', 'no effect', 'poor effect', or 'very poor effect'. These responses were scored from + 2 to -2. When the data of the trial were analysed it was found that there was no significant difference between the ratings for pemoline and placebo, and it was decided, therefore, to express each patient's score as the algebraic sum of the fourteen daily ratings (the treatment rating score).
Results
As predicted, patients with favourable attitudes towards doctors rated treatment as being more beneficial than did those with less favourable attitudes (Fig 1) . The rank order correlation between scores on the attitude scale and the treatment rating scores was 0-38 (P <0 05 1 tail).
Our expectations regarding the personality variables were only partially borne out. As anticipated, the more neurotic tended to report better effects from treatment than did the less neurotic (Fig 2) , although the rank order correlation of 033 between neuroticism and treatment rating scores just failed to reach significance. Contrary to expectation the correlation with extraversion, though low and non-significant, was negative rather than positive. In both the clinical trial and the test-retest study we obtained low and non-significant correlations between the attitude and personality measures. There was a slight tendency for there to be a negative correlation between favourable attitudes and both neuroticism and extraversion, but in neither study were the correlations above 0-2. We conclude, therefore, that attitudes towards physicians and treatment, at least as assessed by the present method, are independent of these two personality dimensions.
Discussion
Three conclusions can be drawn from the results of this study: (1) Variations in patients' reports about the efficacy of a particular treatment were not random but could be attributed in some degree to measurable aspects of the patient's personality and his attitude towards doctors and treatment.
(2) Attitude appears to play a more important role than either of the personality variables considered, although this finding needs to be confirmed in other studies employing larger samples before this conclusion can be accepted with confidence. (3) This attitude appears to be unrelated to either neuroticism or extraversion; this is an important point since any multiple prediction is enhanced, if the predictor variables are uncorrelated.
This study has certain limitations: (1) We recognise that attitudes to doctors and treatment are likely to be complex and that the reaction to an individual practitioner may be at variance with a patient's evaluation of a wider range of doctors with whom he has been in contact. Such reactions are likely to be of importance. For example, Uhlenhuth et al. (1959) found that two doctors who, despite double-blind conditions, obtained different results with meprobamate and phenobarbital as compared with placebo, differed in the way they were described by their patients; 'dependable' and 'helpful' being adjectives applied significantly more to the one than the other.
(2) Personality variables other than those assessed in the present study may well be of importance. For example, comparatively little work has been done on the relationship between types of suggestibility and the outcome of treatment.
(3) In this study we have dealt with the patient's evaluation of treatment rather than an objective criterion of change. Although this method is appropriate when considering feelings of lassitude, it would be interesting to study the effects of non-specific variables in illnesses where changes can be observed and recorded objectively for example, diseases of the skin. Studies such as that described in this paper are of importance in both experimental and clinical medicine, for not only will they enhance our ability to predict individual reactions to treatment, but they also describe those variables which should be controlled when assessing the therapeutic value of new treatments. In clinical trials it is necessary to separate the effect of the administration of the medication from the effects of the pharmacologically active compounds which it contains. The effect produced by the administration of the medication is generally known as a subjective response. This is produced by a mechanism arising through the individual's personality make-up, and not necessarily through the action of an active compound on the nervous system; the latter may, however, show itself by similar symptoms and signs. In order to assess the effect of the administration of medication, the administration of inactive compounds is compared with that of active compounds. Gaddum (1954) has suggested that the term 'dummy tablet' should be used for the inactive medication; he points out that the word placebo means a medicine given more to please than to benefit the patient. He defines a dummy tablet as a counterfeit object which is intended to have no effect. Modell & Garrett (1960) show that a dummy tablet may be used in a clinical trial as a scientific tool in order to discover the origin of any effects which treatment may have. They define placebo action as the response to the act of taking medication, in contrast to the pharmacodynamic action of the medicament. Analysis of the effects produced by the dummy tablet enables the investigator to determine the extent to which the dummy tablet is acting as a placebo; it is, however, most improbable that his intention, that the dummy tablet shall have no effect in a trial in which subjective responses are being observed, will ever be wholly fulfilled. The problem which then faces him is why the individuals in the trial are placeboreactors and whether the degree of placeboreaction can be determined before the trial starts.
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The Response to the Placebo
In order to compare the effects of the dummy and the active tablets, it is essential that the recipients do not know which tablets they are receiving. If volunteer subjects are taking part, effects may occur after administration of the dummy tablets which resemble those of the active compounds even though the subjects do not know in what order the tablets are being administered. Precautions are taken in double-blind trials on volunteer subjects so that neither the observer nor the subjects know the order of administration of the active and inactive tablets. This is because the observer is capable of suggesting to himself that pharmacological effects are arising from the dummy tablets (Letemendia & Harris 1959) .
Pharmacological effects may also occur in the volunteer subjects in double-blind trials who have received inactive tablets as is shown in Fig 1  (Wilson & Huby 1961 ). In this experiment lactose, caffeine, thiopropazate and quinalbarbitone were administered in random order to 54 volunteers. The order of administration was unknown to both subjects and observers, although the subjects were told that they would be receiving either an inactive, a stimulating, a relaxing or a sleeping 100 . the administration of lactose. The drug which they thought they had received is shown in the middle line and the percentages of the total who thought this by the narrow vertical columns. The percentages of the latter subjects, who reported effects which could be attributed to the active drugs, are shown in the top line and by the broad vertical columns. C, T, Q indicate the percentages ofsubjects showing effects ofcaffeine, thiopropazate and quinalbarbitone respectively tablet on each occasion. After they had taken each tablet, the subjects marked on a form the effects which they attributed to the action of that particular tablet and indicated which drug they thought they had received. The drugs which the subjects thought they had received after they had actually received lactose is shown in the second bottom line and the percentages of the total number of subjects who thought they had received those drugs are shown in the narrow vertical columns. The percentages of these subjects who had effects which could definitely be assigned to an action of each of the active drugs which they might have received is shown in the top line and by the broad vertical columns.
These results show that effects attributable to pharmacologically active compounds may appear in subjects who think they have had an inactive tablet as well as in subjects who think they have had pharmacologically active compounds. In the former, the effects presumably resulted only from the act of taking a tablet; in the latter, some autosuggestion may have been taking place. There was, however, insufficient evidence to determine whether the subjects decided that they had received an active tablet and the effects resulted from this decision; or whether the effects appeared spontaneously and, on the basis of this, the subjects reported that they had received the active compound. Glaser & Whittow (1954) have reported that more pronounced symptoms occur after the administration of a dummy tablet if the subjects have previously received an active drug of similar appearance. This suggests that the decision that an active drug has been taken is primary, and that the report of its effects is secondary to this. Some of the subjects said that they would like to receive not only the active tablets, but also the dummy tablet, again. Presumably the tablets had a pleasant effect on these subjects; in this trial, therefore, the dummy tablets had the effects of placebo tablets.
An Analysis ofthe Relationship between the Dummy Tablet and the Placebo
The dummy tablet is one of the factors in a clinical trial which is affected by the agents in the trial. The agents are the subject or patient, observer or doctor, and the relationship between these human agents; the design of the trial is also an agent which attempts to take into account, and is related to, all the other agents. The agents themselves, and their interactions, can give rise to distortions in the course of the trial through their influence on the factors which are built into the trial. Suggestion by the human agents can influence Proceedings ofthe Royal Society ofMedicine the action of the dummy tablet and change it into a placebo, just as the human agents consciously and unconsciously may be able to influence other factors in the trial to a greater or lesser extent (Table 1) . Lasagna & Meier (1959) make the general statement: 'If a subject can voluntarily affect some measurement being studied, it is a simple matter to bias the results regardless of placebo controls.' Crofton (1958) points out that if no satisfactory treatment has been previously available when a trial is being designed, it must be decided whether the trial should be single blind or double blind. This will also apply to trials in which volunteer subjects are being used. In ideal double-blind trials any psychological effect of treatment should be the same in the two groups, and it is argued that much better comparisons may be made of any apparent toxic side-effects of the drug under test. On the other hand, Lasagna & Meier (1959) have pointed out that one misconception about dummy tablets is the belief that they always fool the human agents involved in the trial. When volunteers are being used in cross-over tests in trials, they can recognize different effects of the different tablets if any subjective effects are being produced at all. When different treatments are being investigated which produce greater or lesser, or different, subjective effects, the patient, and generally the doctor also, can recognize these effects. In trials on normal volunteer subjects, the subjects volunteer for the trial knowing that they are going to receive medication which will produce some abnormality which the observer will attempt to measure. Scadding (1958) has made it the first point in describing the ethics of trials that patients must be willing to enter the trial. The doctor and patients in such trials therefore know that a new form of treatment will be compared with an older form, and possibly with dummy tablets. Under these circumstances, all the human agents involved in the trials are looking for effects and even if they do not overtly mention them, the agents will suggest to themselves causes for the effects.
Incorporated in the design of the trial are all the techniques of trial methodologyquestionnaires, single or double blindness, constitution and forms of medication, numbers of patients and subjects, types of doctors and observers, and methods of clinical investigation. The design of the trial is an agent in the trial; it is as important as the other agents, and perhaps more influential because it binds them all together. Faulty design can give rise to distortion of the factors and produce error in the results in the same way as the other agents (Table 2) . Lasagna & Meier (1959) point out that the design of clinical trials fortunately negates the partial breaking down of double-blind deception in this way. When a large number of subjects are being used, when subjective alterations produced in the subjects by the drugs can be confirmed by objective investigation, and when a large number of controls can be included in the design of the trial, the fact that doctors and patients may guess correctly which is the active treatment may make little difference to the results of the trial. However, when only subjective effects can be recorded, when drugs are being administered which alter the personalities of the subjects, and when those who design the trial are not sure what the relation is between the pharmacological effects of the drugs and the personality and behaviour changes which may be taking place in the subjects, the importance of the personalities of the individual subjects becomes much greater (Sargant & Dally 1962) . Tibbetts & Hawkings (1956) have suggested that 'it is hard for a team to maintain its enthusiasm about the use of an inert substance unless that enthusiasm is fixed and maintained by a specific objective, such as a research project; and it may well be that enthusiasm is one of the more effective ingredients of the therapeutic situation'. The investigative power of the observers may be affected by their knowledge of the nature of the medication under single-blind conditions (Tuberculosis Society of Scotland 1957) as much as when they are working under double-blind conditions (Letemendia & Harris 1959) . It is manifest that the actions of the drugs and the carrying out of the trial may be seriously influenced by its design. The distortions which are capable of introduction into its design certainly cannot always be prevented. Even though a large number of controlling factors may be introduced, the distortion which can be introduced by the agents will still be present. Modell (1960) has pointed out that the object of a clinical trial is to obtain maximum sensitivity in the evaluation of an active drug. He states: 'The use of appropriate controls merely serves to prevent extraneous forces from swinging the balance erroneously; not only does this fail to increase the sensitivity of the method but if used merely to balance out extraneous forces by the process of "dead-weighting" it may even make it less sensitive.' The appropriate controls are the factors without .which modern trials cannot accurately be performed. Increase in the number of factors in a trial increases the amount of deadweight which can be distorted by the agents but does not affect the agents themselves. Detection of the pharmacological effect of an active drug on the patient is superimposed on the framework of the agents and factors in the trial.
An Analysis ofthe Relationship between Bias and the Placebo
The detection of effects which arise from other sources than those wholly attributable to the pharmacological actions of the drugs is as important as detection of the effects due to these drugs. Effects which arise from other sources than the drugs in the course of a trial give rise to bias. 'Bias' is defined in the Shorter Oxford English Dictionary as 'an indication, leaning, or bent'; it has been used in a figurative sense to mean 'prejudice' since 1572. Lasagna & Meier (1959) use the meaning 'prejudice' when they refer to 'bias', and they indicate that 'bias', when so defined, may be introduced into trials by way of the observer, the patient, the doctor-patient relationship and into the placebo controls. Modell (1960) states that the so-called placebo action of drugs exerts considerable force on patient response and that all clinical evaluations must reckon with bias. In their use of the term, these workers imply that bias appears in clinical trials and gives rise to distortion or error in the results.
Other items are involved in clinical trials which influence symptoms or subjective experiences (Modell & Houde 1958) . These items are the factors which are included in clinical trials in order to prevent extraneous forces from swinging the balance in a trial erroneously, so that bias occurs and errors appear in the results. The factors may be closely associated with the agents but reference can be made to them separately from the agents. The quantity and quality of the bias in a trial arises from the effect of the distortion produced by the agents on the factors. The errors obtained in the results of a trial are simply the recorded errors which arise from the effect produced by distortion on the factors. It is often assumed that the placebo is a fixed and stable point in a trial to which reference can be made. However, the stability of the placebo depends upon stability in, and between, the agents. If the stability of the agents alters, the placebo may produce abnormal positive or negative effects which produce bias in the trial. The placebo is only a distorted factor in the trial; in the absence of the dummy tablet it is generally acknowledged that a satisfactory trial cannot be performed. Lasagna & Meier (1959) have pointed out that a possible source of error in clinical trials is the frequent use of volunteers as subjects for studying the actions of drugs. The volunteers are generally healthy subjects, or patients suffering from a disease for which the active drug is not the usual form of treatment, or subjects in whom a pathological state is temporarily induced. The results of these studies may then be applied clinically to patients. It must be realized that there are differences between these two situations. In the former, volunteer healthy subjects are being used and the observer is looking for positive pharmacological effects which can be attributed to the action of the drugs. The relationship between the agents is that of observer and subject, and the subject is often paid for taking part in the trial or gains some material advantage. Such pharmacological effects as do occur are decremental to the stable healthy state of the subject and are expected to disappear as soon as the treatment stops. The subject does not look to the observer for treatment, help and advice in the same way as a patient appeals to his doctor. In the latter situation the doctor's treatment is expected to produce alleviation of pre-existing symptoms and signs in a pathological individual. The effect of the doctor's treatment is to take away unwanted symptoms; such therapeutic effects as may occur are decremental to the pathological state of the patient and are expected to restore a normal state of health.
A doctor may compare the effects of analgesics on his patient's pain but in these circumstances the relationship between doctor and patient is different, and probably closer than that between observer and subject, even though the same drugs may be used in each trial. This difference which may arise in the assessment of pain between volunteer subjects and patients has been recognised by ; to avoid it they have designed a method for assessing the analgesic power of drugs which is based on the capacity of the drug under trial to relieve naturally pccurring pain which arises as a consequence of disease. They suggest that naturally occurring pain consists of the perception of painful stimuli and the psychic modification of these stimuli, whereas experimentally produced pain consists only of the former. The psychic modification of painful stimuli is influenced by narcotic agents ), but it is also influenced by the personalities of the patients and by their reaction to the placebo . The subject has much less emotional need to believe the observer when he is told that the treatment will relieve his pain in the laboratory than when the doctor says this to his patient in hospital. The relationship between the agents is different and the distortion which they can be expected to produce on the factors will correspondingly be different. It may therefore be expected that the results of the trials will differ in the quality and quantity of the observed effects.
The Measure ofReaction to the Placebo have defined patients who are relieved of their symptoms as placeboreactors; they used the relief of severe wound pain by the injection of saline as their example of reaction to a placebo. They found that there was a significantly higher incidence of relief from morphine in the placebo-reactors than in the nonreactors. They examined the psychological characteristics of their patients and found significant differences in the personality structures, attitudes, habits and educational background between reactors and non-reactors. They suggested that there was a certain psychological set in the reactors which predisposed to placebo response and from the Rorschach psychodiagnostic test they concluded that the reactors were more productive of responses, more anxious, and preoccupied with internal bodily processes. Joyce (1959) has followed up their suggestions by the use of the Autonomic Awareness Questionnaire (Mandler et al. 1958 ) and other tests, and concludes that it is possible to distinguish significantly between placebo reactors and nonreactors.
An investigation on a small number of volunteer female students (Rick & Wilson 1962, un- published) lends support to, and extends the results of and Joyce (1959) .
In this investigation 18 female students were classified on the basis of Heron's two-part personality measure (Heron 1956 ) as sociable, unsociable, and emotionally maladjusted; there were 6 subjects in each class. The subjects completed the Autonomic Awareness Questionnaire and the short form of the Maudsley Personality Inventory. All the subjects received tablets of lactose and atropine sulphate (1 900 mg) by mouth on separate occasions. They were told that they might receive a 'pep' tablet or an inactive tablet on either occasion; they were also told that if they had received the pep pill their vision might be slightly blurred after the experiment. They were given no further information about the effects of the tablets. Pulse rate and visual near point were 20 SectionofExperimentalMedicine and Therapeutics 785 measured when they took the pill, and at half hourly intervals thereafter for two hours.
Although the investigation was performed on only a small number of subjects, a significant correlation was found between Heron's sociable subjects and their pharmacological response to atropine. Their responses differed significantly from the reactions of the unsociable subjects (P= 002 for pulse; P=0 05 for near point). It was therefore concluded that the sociable subjects tended to have a more active sympathetic component. The emotionally unstable tended to have higher resting values for pulse rate and near vision than the two normal groups, and their response to the effect of atropine on the near point was significantly greater than that of the other groups. In 4 of the 6 subjects in each of Heron's groups consistent scores were obtained with the Maudsley Personality Inventory. On the basis of this consistency, there appeared to be some correlation between Heron's sociable, unsociable and maladjusted groups, and Eysenck's extrovert, introvert and neurotic groups. WVhen the results of the Autonomic Awareness Questionnaires were analysed, it was found that the scores differed significantly between the maladjusted and the two normal groups (P=0-025), the maladjusted scoring significantly higher; it was also found that 3 of the 5 subjects who had a high score on the questionnaire had a response to the placebo even though none of them stated that they had received the active tablet.
It appears, therefore, that the Autonomic Awareness Questionnaire may be of limited value in picking out subjects who react to the administration of a placebo, and there is some evidence that the extroverted sociable subject reacts to the administration of atropine by signs of more pronounced sympathetic activity than occur in the unsociable introverted subject. have suggested that individuals of the former type are more likely to be placebo reactors.
Bias and the Sensitivity of Clinical Trials Trouton (1957) has objected to the low degree of consistency in Lasagna's experiments on placebo reactors. From the suggestions made earlier it can be deduced that consistency of reaction to the placebo can only occur if a high and constant degree of distortion is brought to bear on the factors by the agents in the trial.
Assessments of the response to placebos in terms of personality measurement have not been shown to be very effective in terms of consistency or reliability. When it is realized, however, that such assessments only provide measurements about one of the agents involved in clinical trials, it cannot be expected that they will provide anything approaching 100% accuracy in forecasting the reaction to a dummy tablet in a particular trial. Distortion leading to error in the results may be introduced by any or all of the agents. Tests of the investigative capacity of the observers are as important as personality tests on the subjects; critical examination of the factors introduced by the techniques of the trial are as important as assessment of the doctor-patient relationship. It is only by examining the degree of distortion produced by the agents individually and together that the bias, which is present to a greater or lesser degree in all trials, can be analysed and removed. Bias is an overall weight in each pan of the balance which is used for clinical evaluation of drugs. This weight can, however, be broken down into its component parts, and when this is done bias is found to be a weight which varies during the course of a trial. The variation is produced by the agents involved in the trial. A critical and full investigation of all the agents gives some indication of the distortion in a clinical trial. Only by doing this will it be possible to evaluate the swaying influence of bias and so to reduce the dead-weighting of the factors in clinical trials.
